, Tracking Stock Market Picks
Enter Symbol:
Cleveland Biolabs, Inc. (CBLI) [hlAlert]

up 90.81 %

Cleveland Biolabs, Inc. (CBLI) rated Buy with price target $4 by Cantor Fitzgerald

Posted on: Thursday,  Mar 21, 2013  8:25 AM ET by Cantor Fitzgerald

Cantor Fitzgerald rated Buy Cleveland Biolabs, Inc. (NASDAQ: CBLI) on 03/21/2013, when the stock price was $1.96. Since
then, Cleveland Biolabs, Inc. has gained 90.82% as of 08/27/2015's recent price of $3.74.
If you would have followed this Cantor Fitzgerald's recommendation on CBLI, you would have gained 90.81% of your investment in 889 days.

Cleveland BioLabs, Inc. (CBLI) is a development-stage biotechnology company. The Company is focused on developing cancer treatment, tissue protection and biodefense drugs. The Company?s pipeline includes products from two primary families of compounds: protectans and curaxins. CBLI is developing protectans as drug candidates that protect healthy tissues from acute stresses such as radiation, chemotherapy and ischemia (pathologies that develop as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies.

Cantor U.S. Equity Research provides timely and insightful opinions on select stocks. We look at key drivers of the stock price, including company and industry fundamentals, capital markets influences and overall economic trends to provide critical and in-depth analysis. Our focus is on small and mid-cap companies in the following sectors: * Marine Transportation * Life Sciences * Clean Technology & Energy Efficiency * Real Estate * Communications Technology * Internet * Enterprise Software
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/21/2013 8:25 AM Buy
1.96 4.00
as of 12/13/2013
1 Week down  -7.31 %
1 Month down  -21.91 %
3 Months down  -34.10 %
1 YTD down  -41.83 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy